Posted by Michael Wonder on 28 Sep 2022
CSL receives manufacturing and marketing authorisation in Japan for “Berinert SC injection 2000,” as a medicine for prevention of acute hereditary angioedema attacks
26 September 2022 - At home subcutaneous therapy advances treatment options for patients and marks a milestone in 40 years of delivering on CSL’s promise to the HAE patient community.
CSL Behring announces that it has received a manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for “Berinert S.C. Injection 2000,” a lyophilised human C1-esterase inhibitor concentrate for subcutaneous injection in plasma derivative, for the prevention of acute hereditary angioedema attacks.
